NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

27/08/2026

1

Buy

$25.50

21.31%

Neuren Pharmaceuticals' first half revenue was effectively pre-released via Acadia’s quarterly updates, hence the result provided granularity on R&D spend and cash position, Bell Potter notes.

Opex increased 75% year on year but came in lower than the broker's forecast, resulting in an earnings beat. Impressively, the Daybue royalty income stream alone continues to exceed operating costs.

The dividend provides a moderate yield for shareholders, however capital growth will dominate future shareholder returns and is the reason to own the stock in Bell Potter's view, particularly as the binary Phase 3 readout in PMS draws closer. 

Buy and $25.50 target retained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 33.00 cents and EPS of 35.50 cents.
Bell Potter forecasts a full year FY27 dividend of 37.00 cents and EPS of 53.60 cents.

30/08/2026

1

Buy

$24.76

17.79%

Canaccord Genuity maintains a Buy rating for Neuren Pharmaceuticals with a $24.76 target price following the release of 1H26 results featuring a $33.2m royalty stream and a maiden dividend declaration.

The company declared an initial 15c per share dividend based on a target payout ratio of 70% to 100%, and finished the half with $287m in cash.

Reported EBIT of $7.6m and NPAT of $4.9m fell below forecasts due to higher research and development expenses associated with advancing the NNZ-2591 pipeline.

Near-term milestones include a planned Daybue commercial launch in Germany triggering a US$35m payment and upcoming top-line results from a Japanese trial.

The analyst views the established royalty franchise as a predictable funding source for second-drug development, noting clearer visibility on the NNZ-2591 clinical pathway is expected to unlock remaining valuation upside.